Neurosteroid

VistaGen Announces Publication in CNS Spectrums Detailing Proposed Mechanism of Action of Its Investigational Neuroactive Nasal Sprays for Anxiety and Depression Disorders

Retrieved on: 
Wednesday, December 30, 2020
Psychiatry, Branches of biology, Psychology, Psychiatric diagnosis, PH10, Abnormal psychology, 4-Androstadienol, Anxiety, Neurosteroid, Mental disorder, Pherine

PH94B and PH10 were discovered and developed for their specific therapeutic potential to treat anxiety and depression disorders, representing a new class of neuropharmaceuticals, said Dr. Monti.

Key Points: 
  • PH94B and PH10 were discovered and developed for their specific therapeutic potential to treat anxiety and depression disorders, representing a new class of neuropharmaceuticals, said Dr. Monti.
  • Bringing hope to individuals who continue to suffer from anxiety and depression is at the core of VistaGens mission, added Shawn Singh, VistaGens Chief Executive Officer.
  • CNS Spectrums, 1-7. doi:10.1017/S109285292000190X
    PH94B is an innovative odorless investigational synthetic neuroactive steroid nasal spray with therapeutic potential in multiple mental health disorders involving anxiety or phobia and is designed to have a rapid-onset.
  • VistaGen is currently preparing PH94B for Phase 3 development as a potential acute treatment of anxiety in adults with SAD.